MedImmune LLC

MedImmune LLC logo
๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
Subsidiary
Established
1987-01-01
Employees
5K
Market Cap
-
Website
http://medimmune.com

To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease

First Posted Date
2015-11-10
Last Posted Date
2018-03-19
Lead Sponsor
MedImmune LLC
Target Recruit Count
48
Registration Number
NCT02601560
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, Falls Church, Virginia, United States

A Study in Adult Subjects With Select Advanced Solid Tumors

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-10-22
Last Posted Date
2019-01-08
Lead Sponsor
MedImmune LLC
Target Recruit Count
40
Registration Number
NCT02583165
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, Houston, Texas, United States

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

First Posted Date
2015-10-15
Last Posted Date
2019-06-18
Lead Sponsor
MedImmune LLC
Target Recruit Count
47
Registration Number
NCT02576548
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, Nashville, Tennessee, United States

A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2015-09-22
Last Posted Date
2018-12-19
Lead Sponsor
MedImmune LLC
Target Recruit Count
53
Registration Number
NCT02556463
Locations
๐Ÿ‡ซ๐Ÿ‡ท

Research Site, Villejuif, France

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

First Posted Date
2015-09-15
Last Posted Date
2019-02-27
Lead Sponsor
MedImmune LLC
Target Recruit Count
32
Registration Number
NCT02549651
Locations
๐Ÿ‡ฌ๐Ÿ‡ง

Research Site, Leicester, United Kingdom

A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-09-14
Last Posted Date
2019-04-05
Lead Sponsor
MedImmune LLC
Target Recruit Count
113
Registration Number
NCT02548585
Locations
๐Ÿ‡ฉ๐Ÿ‡ช

Research Site, Neuss, Germany

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-08-17
Last Posted Date
2019-03-13
Lead Sponsor
MedImmune LLC
Target Recruit Count
103
Registration Number
NCT02524782
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Research Site, San Antonio, Texas, United States

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-08-17
Last Posted Date
2018-02-15
Lead Sponsor
MedImmune LLC
Target Recruit Count
113
Registration Number
NCT02525094
Locations
๐Ÿ‡ณ๐Ÿ‡ฟ

Research Site, Wellington, New Zealand

A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma

First Posted Date
2015-08-10
Last Posted Date
2024-12-12
Lead Sponsor
MedImmune LLC
Target Recruit Count
433
Registration Number
NCT02519348
Locations
๐Ÿ‡จ๐Ÿ‡ณ

Research Site, Taoyuan City, Taiwan

A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-07-31
Last Posted Date
2017-06-21
Lead Sponsor
MedImmune LLC
Target Recruit Count
21
Registration Number
NCT02512900
Locations
๐Ÿ‡ต๐Ÿ‡ฑ

Research Site, ลรณdลบ, Poland

ยฉ Copyright 2024. All Rights Reserved by MedPath